News Archive
- Year 2012 (15 items)
- Changes to Biohit Oyj’s management
- INTERIM REPORT OF THE BIOHIT GROUP 1 JANUARY TO 31 MARCH 2012
- Biohit Oyj has changed its reporting after the divestment of the liquid handling business
- Changes to Biohit Oyj’s management
- Resolutions of the Annual General Meeting of Biohit Oyj
- Publication of Biohit Oyj's Annual Report 2011
- CORRECTION TO NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING
- NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING
- Biohit Oyj has begun a clinical study, the purpose of which is to determine the capacity of company´s new BioAcetium product to treat Helicobacter pylori infection
- The Biohit Group's financial statements bulletin 1 January-31 December 2011
- Biohit Oyj’s GastroPanel biomarkers suggested as the first-line method for examination of gastric functions and risk conditions
- Biohit Oyj records a goodwill impairment in its 2011 Financial Statements
- Biohit Oyj will pay the capital loan and its accumulated interest back to the company’s principal shareholders
- Holders of Biohit Oyj convertible bond sell loan back to company
- Biohit Oyj to offer holders of convertible bonds possibility to sell loan back to company
- Year 2011 (28 items)
- Communications procedure of Biohit Oyj on the publication of a press release on business sales
- Changes to Biohit Oyj’s management
- Biohit's financial information in 2012
- Biohit Oyj and Sartorius Lab Holding GmbH complete sale of liquid handling business, Biohit Oyj revises risk outlook
- Semi Korpela appointed new President and CEO of Biohit Oyj
- Decision made at Biohit Oyj’s Extraordinary Shareholder Meeting
- Notice of the Extraordinary Shareholder Meeting of Biohit Oyj
- Biohit decides to sell its liquid handling business to Sartorius Lab Holding GmbH and changes its financial guidance
- Interim report of the Biohit group 1 January to 30 September 2011
- Notification of change in number of shares and voting rights, in accordance with the Securities Markets Act, Chapter 2, Section 10
- Biohit Oyj to arrange a directed share issue to Sartorius Lab Holding GmbH
- Interim report of the Biohit Group 1 January to 30 June 2011
- New ergonomics product from Biohit
- Changes in the Management Team of Biohit Oyj
- Biohit launches a new electronic pipette for precise dispensing in small volumes
- Interim report of the Biohit Group 1 January to 31 March 2011
- Osmo Suovaniemi becomes Chairman of the Board of Directors of Biohit Oyj
- Resolutions of the Annual General Meeting of Biohit Oyj
- New desktop liquid handling instrument from Biohit
- Notice of Annual General Meeting of Biohit Oyj
- Earthquake in Japan has caused only minor damage to Biohit subsidiary
- Biohit's Annual Report 2010 has been published
- Financial targets of Biohit Oyj
- Biohit's Financial Statements and Board of Directors' Report for 2010 have been published
- The Biohit Group's Financial Statement Bulletin 1 January – 31 December 2010
- Proline Plus mechanical pipette family expands with new member
- Terveystalo broadens its range of services with a stomach health test developed by Biohit, Finland
- ISO 8 cleanroom certification for Biohit tip production
- Year 2010 (24 items)
- Changes in the diagnostics business of Biohit
- Biohit Oyj's financial information in 2011
- Profit warning: Biohit forecasts lower financial result than last year, despite sales growth
- Interim Report of the Biohit Group 1 January to 30 September 2010
- Biohit Oyj expands its service laboratory offering with acetaldehyde determinations
- Changes in Biohit Oyj’s Diagnostics Management Team
- ColonView FOB Quick Tests in new easy-to-use package
- Interim report of the Biohit Group 1 january to 30 june 2010
- Biohit Oyj to issue convertible bond
- Changes in Biohit Oyj's Management Team
- New President and CEO for Biohit Oyj
- New Acetium capsule designed to reduce carcinogenic acetaldehyde
- Amendments to the Article of Association of Biohit Oyj come into power today
- Interim report of the Biohit Group 1 January to 31 March 2010
- NEW PCR Starter Kit from Biohit!
- Resolutions of the Annual General Meeting of Biohit Oyj
- Biohit's Annual report 2009 has been published
- Notice of Annual General Meeting of Shareholders of Biohit Oyj
- Biohit's Financial Statements and Report of the Board of Directors 2009
- Changes in Biohit Oyj's Management Team
- New Liquid Handling Products Catalogue
- Biohit Group's Financial Statement Release 2009
- New Director appointed to Biohit's Diagnostics business
- New product for elimination of carcinogenic acetaldehyde - Acetium
- Year 2009 (2 items)
- Year 2008 (1 item)
- Year 2007 (1 item)
Changes to Biohit Oyj’s management
02.05.2012 09:30Changes to Biohit Oyj’s management Anu Mickels, MBA (b. 1972) has been appointed Biohit Oyj’s Sales and Marketing Director as from 2 May 2012. She takes over from Terhi Lampén. Mickels previously worked as Marketing Manager for Orion Diagnostiikka Oy from 2008, and prior to that she held sales and communications management positions in Oy Dagmar Ab, from 1999 to 2008. Lampén will continue as Marketing Manager at Biohit Oyj. Semi Korpela, M.Sc. (Econ.) CEO, Biohit Group Tel.: +358 9 773 861 Mobile: +358 40 573 7701 semi.korpela@biohit.fi BIOHIT HealthCare Inn...
INTERIM REPORT OF THE BIOHIT GROUP 1 JANUARY TO 31 MARCH 2012
26.04.2012 09:30Interim report of the Biohit Group 1 january to 31 march 2012 can be read via the following link as pdf-file: Interim report Q1/2012
Biohit Oyj has changed its reporting after the divestment of the liquid handling business
26.04.2012 09:15The announcement of changed reporting can be read via the following link as pdf-file: Changed reporting
Changes to Biohit Oyj’s management
17.04.2012 11:00Changes to Biohit Oyj’s management Panu Hendolin, PhD (molecular medicine), born in 1971, was appointed Head of Research and Development at Biohit Oyj as of 17 April 2012. Hendolin worked at Biohit as Research Manager and Head of Research and Development from 2007 to 2008. Previously, Hendolin worked as a Postdoctoral Researcher at the A. I. Virtanen Institute for Molecular Sciences at the University of Eastern Finland, in several product development and managerial positions at Jurilab Oy Ltd and for the last three and a half years as the Technical Manager responsible for product...
Resolutions of the Annual General Meeting of Biohit Oyj
11.04.2012 18:30Resolutions of the Annual General Meeting of Biohit Oyj The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday 11 April 2012 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2011. Distribution of dividends In accordance with the proposal by the Board of Directors, the AGM decided that the profit for the financial period ended on 31 December 2011 will be recorded in the profit and loss account. In a...
Publication of Biohit Oyj's Annual Report 2011
04.04.2012 14:10Stock exchange release 4.4.2012 02.10 pm Publication of Biohit Oyj’s Annual Report 2011 Today, Biohit Oyj published its 2011 annual report, available as a PDF file from Biohit’s website www.biohithealthcare.com/Investors. The annual report contains a review of information published in 2011. The result for the financial period presented in the 2011 annual report deviates from that published in a financial statement released on 29 February 2012. In the financial statement release, the profit for the financial period was given as €38.7 million. In the...
CORRECTION TO NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING
19.03.2012 15:30CORRECTION TO NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING Biohit Oyj’s stock exchange release of 16 March 2012 contained an error in section C.3 (Instructions for the participants at the Annual General Meeting, Holders of nominee registered shares) regarding the time limit by which a holder of nominee registered shares may ask to be temporarily entered into the company's shareholder register for participation in the General Meeting. In deviation of the notice of the Annual General Meeting, a holder of nominee registered shares, who is entitled to be registered in the comp...
NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING
16.03.2012 17:45NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING Biohit Oyj shareholders are invited to attend the company's Annual General Meeting, which will be held at Hotel Royal at Crowne Plaza, conference room 2, Mannerheimintie 50, 00260 Helsinki, on 11 April 2012, starting at 3:00 pm. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 1:30 pm. A. Matters on the agenda of the Annual General Meeting The following matters will be presented for consideration at the Annual General Meeting: 1. Opening of the meeting 2. Calling...
Biohit Oyj has begun a clinical study, the purpose of which is to determine the capacity of company´s new BioAcetium product to treat Helicobacter pylori infection
02.03.2012 13:00Biohit Oyj has begun a clinical study, the purpose of which is to determine the capacity of company’s new BioAcetium product to treat Helicobacter pylori infection. Biohit Oyj has begun a clinical study in cooperation with the gastroenterology clinic of HUS (Hospital District of Helsinki and Uusimaa) and GastroLääkärit, the purpose of which is to determine the capacity of the new BioAcetium product to eradicate Helicobacter pylori in individuals over 55 years of age who have not been diagnosed with a prior H. pylori infection. Biohit Oyj has developed the BioAcetium product, w...
The Biohit Group's financial statements bulletin 1 January-31 December 2011
29.02.2012 10:30Biohit Oyj Financial Statements Bulletin 29th Feb 2012 10:30 am (as pdf-file via this link).
Biohit Oyj’s GastroPanel biomarkers suggested as the first-line method for examination of gastric functions and risk conditions
17.02.2012 12:00The article published in the authoritative Scandinavian Journal of Gastroenterology was written by 16 gastroenterology specialists from 12 countries. The aim of this group of specialists is to develop the safety and cost-efficiency of the diagnosis, prevention and treatment of dyspepsia, H. pylori infection and atrophic gastritis through international co-operation (www.biohit.fi/ GastroPanel biomarkers:Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers, Scandinavian Journal of Gastroenterology.2012; 47: 136–147). According to the art...
Biohit Oyj records a goodwill impairment in its 2011 Financial Statements
14.02.2012 17:15Biohit Oyj Stock exchange release 14 February 2012 The Board of Directors of Biohit Oyj has decided that Biohit Oyj records a goodwill impairment of EUR 2.6 million in its 2011 Financial Statements. The impairment is based on the goodwill impairment testing required by the IFRS standards and carried out at the year end. Goodwill has been allocated to certain GastroPanel products in the Diagnostics segment. Testing was executed according to the same principles as in the previous year. In 2010, the previous year’s forecast proved to be fairly accurate, but in 2011, actual perfor...
Biohit Oyj will pay the capital loan and its accumulated interest back to the company’s principal shareholders
14.02.2012 17:00Biohit Oyj Stock exchange release 14 February 2012 The Board of Directors of Biohit Oyj has decided that Biohit Oyj will pay the capital loan and its accumulated interest back to the company’s principal shareholders. Biohit’s principal shareholders have granted the company a capital loan of EUR 635,698.80 for product and other business-related development. The accumulated interest on the capital loan on 31st December 2011 is EUR 594,788.49. After the payment of the capital loan and its accumulated interest, a full margin remains on restricted capital and other non-distributable ass...
Holders of Biohit Oyj convertible bond sell loan back to company
02.02.2012 10:15Biohit Oyj Stock exchange release 2 February 2012 The holders of Biohit Oyj’s convertible bond have sold the loan back to the company. On 28 October 2010, Biohit Oyj issued a convertible bond targeted at institutional investors. The value at the moment of issue was EUR 4.05 million. The fixed coupon rate of the bond is 6.5% and it has a five-year maturity. Each share of the loan of EUR 4,500 entitles the holder to exchange the share of the loan for 1,000 B shares with a nominal value of EUR 0.17. The rate of exchange of the share is EUR 4.5. The loan can be exchanged for a ...
Biohit Oyj to offer holders of convertible bonds possibility to sell loan back to company
31.01.2012 11:25Biohit Oyj Stock exchange release 31 January 2012 11.00 AM The Board of Directors of Biohit Oyj has decided at the Board meeting that the company will offer holders of Biohit Oyj convertible bonds to possibility to sell loan back to the company. On 14 December 2011, Biohit Oyj sold its liquid handling business to Sartorius Lab Holding GmbH, and with this sale the financial standing of the company has become significantly stronger. On 28 October 2010, Biohit Oyj issued a convertible bond targeted at institutional investors. The value at the moment of issue was 4.05 million. The fix...